Management of Hypertension with Normal EF Found Incidentally on Routine 2D Echo
For a patient with hypertension and normal ejection fraction discovered incidentally on routine echocardiography, you should target a blood pressure goal of <130/80 mmHg using guideline-directed medical therapy, with drug selection informed by any structural cardiac abnormalities detected on the echo (such as left ventricular hypertrophy or diastolic dysfunction). 1
Initial Assessment and Risk Stratification
The incidental echo finding provides valuable information beyond just confirming normal EF. You must carefully review the complete echocardiogram report for hypertension-mediated organ damage (HMOD), specifically:
- Left ventricular hypertrophy (LVH) - present in up to 15.9% of hypertensive patients 2
- Diastolic dysfunction - found in approximately 29.1% of hypertensive patients even with normal EF 2
- Left atrial enlargement
- Valvular abnormalities (mitral regurgitation, tricuspid regurgitation)
- Wall motion abnormalities suggesting unrecognized prior MI
Research shows that 92.5% of hypertensive patients over 60 have some echocardiographic abnormality, even with preserved EF 3. These findings are not merely academic—they carry prognostic significance and should guide your therapeutic approach.
Blood Pressure Target
Aim for SBP <130 mmHg and DBP 70-80 mmHg 1. The 2025 AHA/ACC guidelines clearly establish this target for patients with hypertension and cardiac comorbidities, even with preserved ejection fraction.
Drug Selection Strategy
Your antihypertensive regimen should be tailored based on the specific cardiac abnormalities found:
If LVH is Present:
- First-line: ACE inhibitors or ARBs - these promote regression of LVH 1
- Add: Thiazide-type diuretics or calcium channel blockers as needed for BP control
- Consider: Mineralocorticoid receptor antagonists (MRA) if additional agents needed 1
If Diastolic Dysfunction is Present:
- Prioritize agents that improve diastolic filling: ACE inhibitors, ARBs, or beta-blockers
- Avoid volume overload - use diuretics judiciously to maintain euvolemia
- Calcium channel blockers (dihydropyridine) can be added safely 1
If Echo is Completely Normal:
- Standard first-line therapy: ACE inhibitor/ARB, thiazide-type diuretic, or calcium channel blocker
- Choice can be based on patient demographics, comorbidities, and tolerability
Critical Pitfalls to Avoid
Do not dismiss the echo as "just normal EF." The presence of structural abnormalities like LVH or diastolic dysfunction represents a continuum toward heart failure with preserved ejection fraction (HFpEF), and approximately 22.7% of hypertensive patients fall into a high-risk category for developing HFpEF 2. These patients also demonstrate significantly increased vascular damage with higher arterial stiffness.
Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) if there is any suggestion of systolic dysfunction or if the patient is at risk for HFrEF, as these have negative inotropic effects 1.
Additional Workup Required
Beyond the echo, the 2024 ESC guidelines mandate 4:
- Serum creatinine and eGFR - repeat annually if CKD present
- Urine albumin-to-creatinine ratio (ACR)
- 12-lead ECG - already done if echo was ordered, but review for LVH criteria or ischemic changes
- Cardiovascular risk assessment using SCORE2 (age 40-69) or SCORE2-OP (age ≥70) if not already at increased risk
Lifestyle Modifications
Implement aggressively alongside pharmacotherapy 4:
- Sodium restriction to <2g/day (approximately 5g salt/day)
- Moderate-intensity aerobic exercise ≥150 min/week plus resistance training 2-3 times/week
- Target BMI 20-25 kg/m² and waist circumference <94 cm (men) or <80 cm (women)
- Mediterranean or DASH diet
- Alcohol limitation to <100g/week (preferably complete avoidance)
- Smoking cessation if applicable
Follow-Up Strategy
- Recheck BP in 1-3 months after initiating or adjusting therapy
- Consider repeat echo in 1-2 years if LVH or diastolic dysfunction present to assess for regression with treatment
- Annual monitoring of renal function and electrolytes, especially if using ACE inhibitors/ARBs or MRAs
- More aggressive monitoring if BP remains uncontrolled or if patient develops symptoms
The key insight is that "normal EF" does not mean "normal heart" in a hypertensive patient. The echo provides a window into subclinical cardiac remodeling that should intensify—not reassure—your approach to BP management 5, 6.